US9511092B2
(en)
|
2013-01-28 |
2016-12-06 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
|
KR20210108497A
(ko)
|
2013-02-26 |
2021-09-02 |
메모리얼 슬로안 케터링 캔서 센터 |
면역치료용 조성물 및 방법
|
KR20150128997A
(ko)
*
|
2013-03-15 |
2015-11-18 |
메모리얼 슬로안-케터링 캔서 센터 |
면역치료용 조성물 및 방법
|
EP3461493A1
(en)
|
2013-03-29 |
2019-04-03 |
Sumitomo Dainippon Pharma Co., Ltd. |
Wt1 antigen peptide conjugate vaccine
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
WO2015095811A2
(en)
|
2013-12-20 |
2015-06-25 |
The Board Institute Inc. |
Combination therapy with neoantigen vaccine
|
US11390921B2
(en)
|
2014-04-01 |
2022-07-19 |
Adaptive Biotechnologies Corporation |
Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
|
JP6759187B2
(ja)
|
2014-04-23 |
2020-09-23 |
ジュノー セラピューティクス インコーポレイテッド |
養子療法用の免疫細胞集団を単離、培養、および遺伝子操作するための方法
|
SG11201609118RA
(en)
|
2014-05-15 |
2016-11-29 |
Univ Singapore |
Modified natural killer cells and uses thereof
|
KR102594343B1
(ko)
|
2014-07-21 |
2023-10-26 |
노파르티스 아게 |
Cd33 키메라 항원 수용체를 사용한 암의 치료
|
PL3177640T3
(pl)
|
2014-08-08 |
2020-11-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Charakteryzujące się wysokim powinowactwem środki terapeutyczne naśladujące PD-11 i sposoby ich wykorzystania
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
AU2015317608B2
(en)
*
|
2014-09-17 |
2021-03-11 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
SG11201703203RA
(en)
|
2014-10-20 |
2017-05-30 |
Juno Therapeutics Inc |
Methods and compositions for dosing in adoptive cell therapy
|
EP3212223B1
(en)
*
|
2014-10-27 |
2021-08-18 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy
|
AU2015338984A1
(en)
*
|
2014-10-31 |
2017-04-27 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for modified T cells
|
EP4310097A3
(en)
|
2014-12-05 |
2024-04-03 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
KR20170108944A
(ko)
|
2014-12-05 |
2017-09-27 |
메모리얼 슬로안-케터링 캔서 센터 |
B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법
|
KR20170108946A
(ko)
|
2014-12-05 |
2017-09-27 |
메모리얼 슬로안-케터링 캔서 센터 |
Fc 수용체-유사 5를 표적화하는 키메라 항원 수용체 및 그의 용도
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
EP3757211A1
(en)
|
2014-12-19 |
2020-12-30 |
The Broad Institute, Inc. |
Methods for profiling the t-cell-receptor repertoire
|
IL252295B2
(he)
*
|
2014-12-19 |
2023-10-01 |
Dana Farber Cancer Inst Inc |
קולטני אנטיגן כימריים ושיטות לשימוש בהם
|
JP6797803B2
(ja)
*
|
2014-12-31 |
2020-12-09 |
セルジーン コーポレイション |
ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法
|
MA41346A
(fr)
|
2015-01-12 |
2017-11-21 |
Juno Therapeutics Inc |
Eléments régulateurs post-transcriptionnels d'hépatite modifiée
|
CN107429254B
(zh)
|
2015-01-30 |
2021-10-15 |
加利福尼亚大学董事会 |
原代造血细胞中的蛋白递送
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
JP6336684B2
(ja)
*
|
2015-03-02 |
2018-06-06 |
イノベイティブ セルラー セラピューティクス シーオー.,エルティディ.Innovative Cellular Therapeutics Co.,Ltd. |
Pd−l1によって誘導される免疫寛容の低減
|
WO2016161415A2
(en)
|
2015-04-02 |
2016-10-06 |
Memorial Sloan Kettering Cancer Center |
Tnfrsf14/ hvem proteins and methods of use thereof
|
JP2018513216A
(ja)
|
2015-04-15 |
2018-05-24 |
プロスペクト チャーターケア アールダブリュエムシー,エルエルシー ディ/ビー/エイ ロジャー ウィリアムズ メディカル センターProspect Chartercare Rwmc,Llc D/B/A Roger Williams Medical Center |
Car−t細胞の肝動脈注入
|
EP3288568A4
(en)
*
|
2015-04-30 |
2019-01-02 |
University of Southern California |
Secretory tnt car cell immunotherapy
|
FI3298033T4
(fi)
|
2015-05-18 |
2023-09-22 |
Tcr2 Therapeutics Inc |
Koostumuksia ja lääkinnällisiä käyttöjä fuusioproteiineja käyttävälle tcr:n uudelleenohjelmoinnille
|
CA2986235A1
(en)
|
2015-05-20 |
2016-11-24 |
The Broad Institute, Inc. |
Shared neoantigens
|
US20180140691A1
(en)
*
|
2015-05-20 |
2018-05-24 |
Sumitomo Dainippon Pharma Co., Ltd. |
Combination use of wt1 antigen peptide and immunomodulator
|
EP3436575A1
(en)
|
2015-06-18 |
2019-02-06 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
TWI773647B
(zh)
*
|
2015-06-23 |
2022-08-11 |
史隆凱特林紀念癌症中心 |
新穎pd-1免疫調控劑
|
CA2986604A1
(en)
*
|
2015-06-26 |
2016-12-29 |
University Of Southern California |
Masking chimeric antigen receptor t cells for tumor-specific activation
|
CA2993431A1
(en)
|
2015-07-31 |
2017-02-09 |
Regents Of The University Of Minnesota |
Nuclease based knockouts of immunological checkpoint genes in immune cells
|
CN105111314B
(zh)
*
|
2015-08-13 |
2019-01-08 |
成都百世博生物技术有限公司 |
一种新型融合蛋白、药物组合物及其制备方法和用途
|
AU2016332725A1
(en)
|
2015-09-29 |
2018-03-22 |
Celgene Corporation |
PD-1 binding proteins and methods of use thereof
|
SG11201801984TA
(en)
*
|
2015-10-01 |
2018-04-27 |
Heat Biologics Inc |
Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
|
CN106350533B
(zh)
*
|
2015-10-09 |
2020-07-17 |
上海宇研生物技术有限公司 |
Anti-PD-L1-CAR-T及其制备方法和应用
|
US20190255107A1
(en)
|
2015-10-09 |
2019-08-22 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
CN105331585A
(zh)
*
|
2015-11-13 |
2016-02-17 |
科济生物医药(上海)有限公司 |
携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
US10533157B1
(en)
*
|
2015-12-03 |
2020-01-14 |
Nantbio, Inc. |
Recombinant NK cells expressing co-stimulatory molecules
|
BR112018011336A2
(pt)
|
2015-12-04 |
2018-12-04 |
Memorial Sloan-Kettering Cancer Center |
anticorpo anti-fcrl5 isolado ou um fragmento de ligação ao antígeno do mesmo, anticorpo scfv anti-fcrl5 isolado, anticorpo isolado ou porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico isolado, vetor de expressão, célula hospedeira, método para detectar fcrl5 em uma célula ou tecido inteiro, método para tratar câncer em um indivíduo, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo, kit para tratar câncer
|
WO2017133175A1
(en)
*
|
2016-02-04 |
2017-08-10 |
Nanjing Legend Biotech Co., Ltd. |
Engineered mammalian cells for cancer therapy
|
AU2017224843A1
(en)
*
|
2016-02-25 |
2018-08-23 |
Cell Medica Switzerland Ag |
Binding members to PD-L1
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
US20190346442A1
(en)
|
2016-04-18 |
2019-11-14 |
The Broad Institute, Inc. |
Improved hla epitope prediction
|
WO2017192924A1
(en)
|
2016-05-04 |
2017-11-09 |
Fred Hutchinson Cancer Research Center |
Cell-based neoantigen vaccines and uses thereof
|
CN105950561A
(zh)
*
|
2016-05-26 |
2016-09-21 |
江苏杰晟生物科技有限公司 |
一种靶向乳腺癌干细胞的双特异性嵌合抗原受体基因修饰的t淋巴细胞的制备方法及其产品
|
MX2018014991A
(es)
|
2016-06-03 |
2019-08-29 |
Memorial Sloan Kettering Cancer Center |
Terapias adoptivas de celulas como opciones de tratamiento temprano.
|
US11390658B2
(en)
|
2016-06-06 |
2022-07-19 |
St. Jude Children's Research Hospital |
Anti-CD7 chimeric antigen receptor and method of use thereof
|
CN107523545A
(zh)
*
|
2016-06-20 |
2017-12-29 |
上海细胞治疗研究院 |
一种高效稳定表达抗体的杀伤性细胞及其用途
|
CN107523547A
(zh)
*
|
2016-06-20 |
2017-12-29 |
上海细胞治疗研究院 |
一种高效稳定表达抑制性抗体的car‑t细胞及其用途
|
CN107523549A
(zh)
*
|
2016-06-20 |
2017-12-29 |
上海细胞治疗研究院 |
一种高效稳定表达激活型抗体的car‑t细胞及其用途
|
CN110088133B
(zh)
*
|
2016-07-29 |
2023-12-08 |
朱诺治疗学股份有限公司 |
抗独特型抗体及相关方法
|
ES2951552T3
(es)
|
2016-07-29 |
2023-10-23 |
Juno Therapeutics Inc |
Polipéptidos inmunomoduladores y composiciones y métodos relacionados
|
AU2017306432A1
(en)
|
2016-08-02 |
2019-03-21 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
WO2018035364A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute Inc. |
Product and methods useful for modulating and evaluating immune responses
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
US10751414B2
(en)
|
2016-09-19 |
2020-08-25 |
Celgene Corporation |
Methods of treating psoriasis using PD-1 binding antibodies
|
EP3515943A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
|
EP4353319A3
(en)
*
|
2016-09-28 |
2024-06-05 |
Atossa Therapeutics, Inc. |
Methods of adoptive cell therapy
|
KR20190062505A
(ko)
|
2016-10-03 |
2019-06-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Hpv-특이적 결합 분자
|
AU2017341048A1
(en)
|
2016-10-07 |
2019-05-23 |
TCR2 Therapeutics Inc. |
Compositions and methods for T-cell receptors reprogramming using fusion proteins
|
US20200016202A1
(en)
|
2016-10-07 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
EP3529359B1
(en)
|
2016-10-18 |
2023-12-13 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes for use in therapy
|
CN107964549B
(zh)
*
|
2016-10-20 |
2020-12-08 |
上海恒润达生生物科技有限公司 |
靶向cd22的嵌合抗原受体及其用途
|
WO2018081784A1
(en)
*
|
2016-10-31 |
2018-05-03 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Artificial antigen presenting cells for expanding immune cells for immunotherapy
|
SG11201903830TA
(en)
|
2016-11-22 |
2019-05-30 |
Nat Univ Singapore |
Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
|
US11851491B2
(en)
|
2016-11-22 |
2023-12-26 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
MX2019006438A
(es)
|
2016-12-05 |
2019-11-28 |
Juno Therapeutics Inc |
Produccion de celulas modificadas para terapia de celulas adoptivas.
|
AR110424A1
(es)
|
2016-12-23 |
2019-03-27 |
Macrogenics Inc |
Moléculas de unión a adam9 y métodos de uso de las mismas
|
WO2018140391A1
(en)
|
2017-01-24 |
2018-08-02 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
CN108395478A
(zh)
*
|
2017-02-04 |
2018-08-14 |
上海恒润达生生物科技有限公司 |
靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途
|
CN116693695A
(zh)
|
2017-02-12 |
2023-09-05 |
百欧恩泰美国公司 |
基于hla的方法和组合物及其用途
|
CN108424461B
(zh)
*
|
2017-02-14 |
2023-03-31 |
亘喜生物科技(上海)有限公司 |
Cd47-car-t细胞
|
WO2018152033A1
(en)
*
|
2017-02-14 |
2018-08-23 |
Promab Biotechnologies, Inc. |
Cd47-car-t cells
|
ES2949364T3
(es)
|
2017-02-17 |
2023-09-28 |
Fred Hutchinson Cancer Center |
Terapias de combinación para el tratamiento de cánceres y trastornos autoinmunitarios relacionados con BCMA
|
AU2018223822A1
(en)
|
2017-02-27 |
2019-07-11 |
Shattuck Labs, Inc. |
CSF1R-based chimeric proteins
|
EP4249503A3
(en)
|
2017-02-27 |
2023-12-20 |
Shattuck Labs, Inc. |
Vsig8-based chimeric proteins
|
SG11201906465YA
(en)
|
2017-02-27 |
2019-08-27 |
Shattuck Labs Inc |
Tigit- and light-based chimeric proteins
|
WO2018182511A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
EP3600356A4
(en)
|
2017-03-27 |
2020-12-23 |
National University of Singapore |
ABBREVIATED NKG2D CHIMERIC RECEPTORS AND USES THEREOF IN IMMUNOTHERAPY WITH NATURAL KILLER CELLS
|
CN107082812B
(zh)
*
|
2017-03-29 |
2018-11-13 |
上海科医联创生物科技有限公司 |
一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
EP3610266A4
(en)
|
2017-04-12 |
2021-04-21 |
Massachusetts Eye and Ear Infirmary |
TUMOR SIGNATURE OF METASTASIS, COMPOSITIONS OF SUBSTANCES AND USES THEREOF
|
EP3612629A1
(en)
|
2017-04-18 |
2020-02-26 |
The Broad Institute, Inc. |
Compositions for detecting secretion and methods of use
|
JP2020517263A
(ja)
*
|
2017-04-19 |
2020-06-18 |
ユニバーシティ オブ サザン カリフォルニア |
がんを治療するための組成物及び方法
|
SG11201909541WA
(en)
|
2017-04-26 |
2019-11-28 |
Eureka Therapeutics Inc |
Chimeric antibody/t-cell receptor constructs and uses thereof
|
CN108864286B
(zh)
*
|
2017-05-16 |
2023-08-29 |
上海恒润达生生物科技股份有限公司 |
靶向cd19的嵌合抗原受体及联合表达抗pd1抗体可变区的方法和及其用途
|
CN111406068A
(zh)
|
2017-05-16 |
2020-07-10 |
约翰霍普金斯大学 |
MANAbody及使用方法
|
US10780119B2
(en)
|
2017-05-24 |
2020-09-22 |
Effector Therapeutics Inc. |
Methods and compositions for cellular immunotherapy
|
CN107245500B
(zh)
*
|
2017-05-27 |
2019-05-17 |
上海优卡迪生物医药科技有限公司 |
一种基于octs技术的淋系白血病car-t治疗载体及其构建方法和应用
|
CN107164410B
(zh)
*
|
2017-05-27 |
2019-09-03 |
上海优卡迪生物医药科技有限公司 |
一种基于octs技术的前列腺癌car-t治疗载体及其构建方法和应用
|
CN107337736B
(zh)
*
|
2017-06-06 |
2019-07-26 |
上海优卡迪生物医药科技有限公司 |
Octs-car双靶向嵌合抗原受体、编码基因、重组表达载体及其构建和应用
|
CN107325185B
(zh)
*
|
2017-06-06 |
2019-09-20 |
上海优卡迪生物医药科技有限公司 |
基于octs-car的抗psca及pdl1双靶向嵌合抗原受体、编码基因及表达载体
|
EP3638218A4
(en)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
SG10201913144TA
(en)
|
2017-07-11 |
2020-03-30 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
CN107245107B
(zh)
*
|
2017-07-18 |
2020-02-07 |
深圳市免疫基因治疗研究院 |
一种基于cd20的嵌合抗原受体及其应用
|
CN107337737B
(zh)
*
|
2017-07-18 |
2020-02-07 |
深圳市免疫基因治疗研究院 |
一种嵌合抗原受体及其应用
|
CN107245106B
(zh)
*
|
2017-07-18 |
2020-06-12 |
深圳市免疫基因治疗研究院 |
一种基于cd10的嵌合抗原受体及其应用
|
CN107312098B
(zh)
*
|
2017-07-18 |
2020-06-12 |
深圳市免疫基因治疗研究院 |
一种基于cd22的嵌合抗原受体及其应用
|
SG11202002105WA
(en)
|
2017-09-11 |
2020-04-29 |
Atossa Therapeutics Inc |
Methods for making and using endoxifen
|
CN107557336B
(zh)
*
|
2017-09-15 |
2020-02-14 |
山东兴瑞生物科技有限公司 |
一种抗muc16安全型嵌合抗原受体修饰的免疫细胞及其应用
|
CN111511388A
(zh)
|
2017-09-21 |
2020-08-07 |
博德研究所 |
用于靶向核酸编辑的系统、方法和组合物
|
CN109554349B
(zh)
*
|
2017-09-27 |
2022-06-24 |
亘喜生物科技(上海)有限公司 |
Pd-1基因表达沉默的工程化免疫细胞
|
CN109554348A
(zh)
*
|
2017-09-27 |
2019-04-02 |
亘喜生物科技(上海)有限公司 |
可诱导分泌抗cd47抗体的工程化免疫细胞
|
EP3687569A1
(en)
|
2017-09-29 |
2020-08-05 |
Cell Design Labs, Inc. |
Methods of making bispecific anti-cd307e and anti-bcma chimeric antigen receptors and uses of the same
|
CN109593721B
(zh)
*
|
2017-09-30 |
2022-11-01 |
亘喜生物科技(上海)有限公司 |
具有自杀基因开关的靶向人间皮素的工程化免疫细胞
|
WO2019070541A1
(en)
|
2017-10-03 |
2019-04-11 |
Juno Therapeutics, Inc. |
HPV-SPECIFIC BINDING MOLECULES
|
JP2021502330A
(ja)
|
2017-10-20 |
2021-01-28 |
フレッド ハッチンソン キャンサー リサーチ センター |
Tigitおよび/またはcd112rを標的とするか、またはcd226過剰発現を含む、組成物および免疫治療の方法
|
WO2019084055A1
(en)
|
2017-10-23 |
2019-05-02 |
Massachusetts Institute Of Technology |
CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
US11066475B2
(en)
|
2017-11-01 |
2021-07-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
|
US11623961B2
(en)
|
2017-11-01 |
2023-04-11 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
|
US20210363260A1
(en)
|
2017-11-13 |
2021-11-25 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
US11649294B2
(en)
*
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
CN109467603B
(zh)
*
|
2017-11-14 |
2020-02-21 |
拜西欧斯(北京)生物技术有限公司 |
抗pd-1抗体及其制备方法和应用
|
EP3710020A4
(en)
*
|
2017-11-14 |
2021-06-23 |
Memorial Sloan-Kettering Cancer Center |
IL-36 SECRECTING IMMUNOREACTIVE CELLS AND RELATED USES
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
WO2019126186A1
(en)
|
2017-12-18 |
2019-06-27 |
Neon Therapeutics, Inc. |
Neoantigens and uses thereof
|
CN109971725B
(zh)
*
|
2017-12-28 |
2024-02-02 |
上海细胞治疗研究院 |
抗体修饰的嵌合抗原受体修饰t细胞及其用途
|
CN109971722B
(zh)
*
|
2017-12-28 |
2023-09-01 |
上海细胞治疗研究院 |
靶向cd19且高水平稳定表达cd40抗体的car-t细胞及其用途
|
CN109971721B
(zh)
*
|
2017-12-28 |
2023-10-31 |
上海细胞治疗研究院 |
自表达cd47抗体的间皮素特异性car-t细胞及其用途
|
CN109971716B
(zh)
*
|
2017-12-28 |
2023-08-01 |
上海细胞治疗研究院 |
自分泌cd47抗体的egfr特异性car-t细胞及其用途
|
MX2020006834A
(es)
*
|
2017-12-29 |
2020-09-03 |
Memorial Sloan Kettering Cancer Center |
Receptores mejorados de antigeno quimerico y usos de los mismos.
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
WO2019136305A1
(en)
*
|
2018-01-04 |
2019-07-11 |
Neumedicines Inc. |
Cell-based and immune checkpoint inhibitor therapies combined with il-12 for treating cancer
|
KR20200110356A
(ko)
*
|
2018-01-15 |
2020-09-23 |
화이자 인코포레이티드 |
키메라 항원 수용체 면역요법을 4-1bb 효능제와 조합하여 투여하는 방법
|
EP3768700A1
(en)
|
2018-03-23 |
2021-01-27 |
Kite Pharma, Inc. |
Chimeric transmembrane proteins and uses thereof
|
SG11202009697RA
(en)
|
2018-03-30 |
2020-10-29 |
Univ Geneve |
Micro rna expression constructs and uses thereof
|
EP3773908A1
(en)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics, Inc. |
T cell receptors and engineered cells expressing same
|
RU2020135966A
(ru)
|
2018-04-05 |
2022-05-06 |
Джуно Терапьютикс, Инк. |
Способы получения клеток, экспрессирующих рекомбинантный рецептор, и родственные композиции
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
CN112368013A
(zh)
*
|
2018-04-26 |
2021-02-12 |
贝勒医学院 |
用于选择性靶向活化的致病性t细胞和nk细胞的自体/同种异体免疫防御受体
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
BR112020025048A2
(pt)
|
2018-06-13 |
2021-04-06 |
Novartis Ag |
Receptores de antígeno quimérico de bcma e usos dos mesmos
|
AU2019288733C1
(en)
|
2018-06-22 |
2023-08-03 |
Kite Pharma, Inc. |
Chimeric transmembrane proteins and uses thereof
|
WO2020037178A1
(en)
*
|
2018-08-16 |
2020-02-20 |
Memorial Sloan-Kettering Cancer Center |
Leucine zipper-based compositions and methods of use
|
WO2020068304A2
(en)
|
2018-08-20 |
2020-04-02 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease target binding and uses thereof
|
WO2020041384A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
|
US20210324357A1
(en)
|
2018-08-20 |
2021-10-21 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
US10780121B2
(en)
|
2018-08-29 |
2020-09-22 |
Shattuck Labs, Inc. |
FLT3L-based chimeric proteins
|
EP3856769A4
(en)
*
|
2018-09-28 |
2022-08-17 |
Memorial Sloan Kettering Cancer Center |
IMMUNOREACTIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
US20210388389A1
(en)
|
2018-10-30 |
2021-12-16 |
Yale University |
Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
|
CN113194715B
(zh)
*
|
2018-10-31 |
2024-03-19 |
赫曼尼根公司 |
用于治疗癌症的材料和方法
|
EP3877055A1
(en)
|
2018-11-05 |
2021-09-15 |
Ludwig Institute for Cancer Research Ltd |
Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof
|
US20210388074A1
(en)
|
2018-11-05 |
2021-12-16 |
Ludwig Institute For Cancer Research Ltd. |
Humanized and variant tgf-beta3 specific antibodies and methods and uses thereof
|
MX2021005594A
(es)
|
2018-11-13 |
2021-10-22 |
Compass Therapeutics Llc |
Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
|
US20210393692A1
(en)
*
|
2018-11-13 |
2021-12-23 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for adoptive cell therapy for cancer
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
WO2020132586A1
(en)
|
2018-12-21 |
2020-06-25 |
Neon Therapeutics, Inc. |
Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
MX2021010670A
(es)
|
2019-03-05 |
2021-11-12 |
Nkarta Inc |
Receptores de antigeno quimerico dirigidos a cd19 y usos de los mismos en inmunoterapia.
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
US20220142948A1
(en)
|
2019-03-18 |
2022-05-12 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
WO2020226854A2
(en)
*
|
2019-04-12 |
2020-11-12 |
The Johns Hopkins University |
Tolerogenic artificial antigen-presenting cells
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
US20220226464A1
(en)
|
2019-05-28 |
2022-07-21 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
CN110343667A
(zh)
*
|
2019-07-17 |
2019-10-18 |
贝赛尔特(北京)生物技术有限公司 |
工程化的免疫细胞及其制备方法和应用
|
US20210040175A1
(en)
*
|
2019-08-05 |
2021-02-11 |
Nantkwest, Inc. |
Artificial Target Cells for in-vitro CAR Cytotoxicity and ADCC validation
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
US20220332780A1
(en)
|
2019-09-10 |
2022-10-20 |
Obsidian Therapeutics, Inc. |
Ca2-il15 fusion proteins for tunable regulation
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
IL292462A
(he)
*
|
2019-11-04 |
2022-06-01 |
Inovio Pharmaceuticals Inc |
תרפיה משולבת לטיפול בסרטן המוח
|
CN112079934B
(zh)
*
|
2019-12-17 |
2021-01-29 |
合源生物科技(天津)有限公司 |
一种靶向cd19的嵌合抗原受体及其用途
|
KR20230044537A
(ko)
|
2020-08-13 |
2023-04-04 |
예일 유니버시티 |
원하는 표현형을 갖는 car t 세포의 조작 및 선택을 위한 조성물 및 방법
|
WO2022036495A1
(en)
|
2020-08-17 |
2022-02-24 |
Utc Therapeutics Inc. |
Lymphocytes-antigen presenting cells co-stimulators and uses thereof
|
US20230322899A1
(en)
*
|
2020-08-28 |
2023-10-12 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Fusion protein enhancing cell therapy
|
CN111925990B
(zh)
*
|
2020-09-02 |
2022-08-26 |
北京立康生命科技有限公司 |
一种针对卵巢癌的Anti-MUC16 CAR-T细胞及其制备方法
|
WO2022097061A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
WO2022109611A1
(en)
|
2020-11-20 |
2022-05-27 |
Simcere Innovation, Inc. |
Armed dual car-t compositions and methods for cancer immunotherapy
|
EP4324916A1
(en)
*
|
2021-04-12 |
2024-02-21 |
Medgene Therapeutics, Inc. |
Method for activating and proliferating cd8 t cells exposed to antigen, cd8 t cells, prepared thereby, having enhanced anticancer activity, and use thereof
|
WO2022235832A1
(en)
|
2021-05-06 |
2022-11-10 |
Ludwig Institute For Cancer Research Ltd |
Compositions and methods for immunotherapy
|
CA3216709A1
(en)
*
|
2021-05-13 |
2022-11-17 |
Katharine C. Hsu |
Nkg2c+ t cells and methods of use thereof
|
WO2023173137A1
(en)
|
2022-03-11 |
2023-09-14 |
Yale University |
Compositions and methods for efficient and stable genetic modification of eukaryotic cells
|
WO2023220644A1
(en)
|
2022-05-10 |
2023-11-16 |
Yale University |
Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy
|
WO2023243890A1
(ko)
*
|
2022-06-15 |
2023-12-21 |
주식회사 셀리드 |
자연 살해 t 세포의 리간드와 암 항원을 적재한 자연 살해 세포를 포함하는 백신
|
WO2023246840A1
(en)
*
|
2022-06-22 |
2023-12-28 |
Wuhan Houxian Biopharmaceutical Co. Ltd. |
Combination of il-12 and ox40l for cancer immunotherapy
|
WO2024064824A2
(en)
|
2022-09-21 |
2024-03-28 |
Yale University |
Compositions and methods for identification of membrane targets for enhancement of nk cell therapy
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
CN115850519B
(zh)
*
|
2022-12-12 |
2023-06-23 |
南京市浦口医院 |
一种靶向MAGE-A1且自分泌CD47 scFv的嵌合抗原受体及其应用
|